Diphtheria - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 82
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D520F9DECEFEN
Leaflet:

Download PDF Leaflet

Diphtheria - Pipeline Review, H2 2016
Diphtheria - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria – Pipeline Review, H2 2016, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diphtheria – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 10, 1, 5, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.Diphtheria.

Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diphtheria (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diphtheria (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diphtheria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Diphtheria Overview
Therapeutics Development
Pipeline Products for Diphtheria - Overview
Pipeline Products for Diphtheria - Comparative Analysis
Diphtheria - Therapeutics under Development by Companies
Diphtheria - Therapeutics under Investigation by Universities/Institutes
Diphtheria - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Diphtheria - Products under Development by Companies
Diphtheria - Products under Investigation by Universities/Institutes
Diphtheria - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co., Ltd
BioClonetics Immunotherapeutics, Inc.
Biological E. Limited
Boryung Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
GlaxoSmithKline Plc
Green Cross Corporation
Indian Immunologicals Limited
Kaketsuken K.K.
LG Life Science LTD.
Panacea Biotec Limited
Prometheon Pharma, LLC
Sanofi Pasteur SA
Serum Institute of India Pvt Ltd
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited
Diphtheria - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diphtheria + pertussis(acellular) + tetanus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diphtheria vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Eupenta - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-1107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-3111A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Diphtheria - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-0103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VN-0105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diphtheria - Dormant Projects
Diphtheria - Discontinued Products
Diphtheria - Product Development Milestones
Featured News & Press Releases
Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta
Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 82

LIST OF TABLES

Number of Products under Development for Diphtheria, H2 2016
Number of Products under Development for Diphtheria - Comparative Analysis, H2 2016
Number of Products under Investigation by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Diphtheria - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
Diphtheria - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016
Diphtheria - Pipeline by Biological E. Limited, H2 2016
Diphtheria - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2016
Diphtheria - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Diphtheria - Pipeline by GlaxoSmithKline Plc, H2 2016
Diphtheria - Pipeline by Green Cross Corporation, H2 2016
Diphtheria - Pipeline by Indian Immunologicals Limited, H2 2016
Diphtheria - Pipeline by Kaketsuken K.K., H2 2016
Diphtheria - Pipeline by LG Life Science LTD., H2 2016
Diphtheria - Pipeline by Panacea Biotec Limited, H2 2016
Diphtheria - Pipeline by Prometheon Pharma, LLC, H2 2016
Diphtheria - Pipeline by Sanofi Pasteur SA, H2 2016
Diphtheria - Pipeline by Serum Institute of India Pvt Ltd, H2 2016
Diphtheria - Pipeline by Sinovac Biotech Ltd., H2 2016
Diphtheria - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Diphtheria - Dormant Projects, H2 2016
Diphtheria - Discontinued Products, H2 2016 79

LIST OF FIGURES

Number of Products under Development for Diphtheria, H2 2016
Number of Products under Development for Diphtheria - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Cancer Cachexia - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 108 pages

Ask Your Question

Diphtheria - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: